Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)
Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria:
- Males or post menopausal or surgically sterile females age 18-75 years of age inclusive.
- Diagnosed with T2DM for > or = 6 months with HbA1c > or = 6.0% but < or = 9.0% while taking stable doses of one oral antihyperglycemic agent but < or = 8.5% when taking two oral antihyperglycemic agents for up to a maximum of 3 months prior to screening.
- Fasting Plasma glucose between 115 mg/dL and 269 mg/dL.
- Fasting C-peptide of > or = 0.8 ng/mL.
- BMI < or = 40 kg/m2.
- Otherwise stable health except for T2DM.
Exclusion Criteria:
- Currently taking a non-oral antihyperglycemic agent.
- Have taken a PPARg agonist within 90 days of screening.
- Known allergy to an approved or investigational GLP-1 receptor analog/agonist.
- Unstable cardiovascular disease as defined in clinical protocol.
- History, symptoms or signs of pancreatitis or severe gastrointestinal disease.
- Personal or family history of medullary thyroid tumors history of Multiple Endocrine Neoplasia Syndrome Type 2.
- Poor glucose control as defined in clinical protocol.
- Clinically significant renal and/or hepatic dysfunction as defined in clinical protocol.
- Absolute requirement for corticosteroids or received systemic steroids within 90 days prior to PB1023 administration.
- Pregnant or lactating females.
- Known history or active alcohol or drug abuse within 12 months prior to screening.
- Positive for HIV, Hepatitis B surface antigen or Hepatitis C antibodies.
- Participating in any other study within 30 days prior to screening.
- Other medical or psychiatric condition which in the opinion of the investigator would place the subject at increased risk.
Sites / Locations
- Diablo Clinical Research
- Prism Research
- Rainier Clinical Research Center, Inc.
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
PB1023 Injection
Placebo (0.9% Sodium Chloride Injection)
Arm Description
Subcutaneous injection PB1023
Subcutaneous Injection Placebo
Outcomes
Primary Outcome Measures
Safety/Tolerability
Safety will be evaluated by analyses of incidence of adverse events of interest (possibly related to the class of drug) and other adverse events. Vital signs, ECGs and safety laboratory parameters will also be presented.
Secondary Outcome Measures
Pharmacokinetic Profile
To characterize the PK profile of PB1023 after single and multiple ascending doses of PB1023. The following parameters will be evaluated: t1/2, AUC(inf), AUC(0-t), Tmax, Cmax, Elimination Rate Constant, Clearance and Distribution.
Pharmacodynamic Response
To assess the pharmacodynamic response of various single and multiple doses of PB1023 (daily fasting plasma glucose and serial glucose (and continuous monitoring as defined in time frame), c-peptide and insulin levels in response to a liquid mixed meal tolerance test (MMTT) pre and post dose) on subjects washed off their baseline oral antihyperglycemic agents.
Full Information
NCT ID
NCT01236404
First Posted
November 5, 2010
Last Updated
May 13, 2013
Sponsor
PhaseBio Pharmaceuticals Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01236404
Brief Title
Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus
Official Title
Phase 1/2a, Randomized, Double-Blind Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of PB1023 Injection Following Single and Multiple Ascending Subcutaneous Doses in Adult Subjects With Type 2 Diabetes Mellitus (T2DM)
Study Type
Interventional
2. Study Status
Record Verification Date
May 2013
Overall Recruitment Status
Completed
Study Start Date
November 2010 (undefined)
Primary Completion Date
November 2011 (Actual)
Study Completion Date
November 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
PhaseBio Pharmaceuticals Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Primary objective:
To evaluate the safety and tolerability of single and multiple ascending doses of PB1023 administered as a subcutaneous (SC) injection in adult subjects with T2DM.
Secondary objectives:
To characterize the pharmacokinetic profile of PB1023 after single and multiple ascending doses of PB1023.
To assess the pharmacodynamic response of various single and multiple doses of PB1023 (daily fasting plasma glucose, and serial glucose, c-peptide and insulin levels in response to a liquid Mixed Meal Tolerance Test (MMTT).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PB1023 Injection
Arm Type
Experimental
Arm Description
Subcutaneous injection PB1023
Arm Title
Placebo (0.9% Sodium Chloride Injection)
Arm Type
Placebo Comparator
Arm Description
Subcutaneous Injection Placebo
Intervention Type
Drug
Intervention Name(s)
Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)
Intervention Type
Drug
Intervention Name(s)
Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)
Intervention Description
Once weekly injections for up to four weeks
Primary Outcome Measure Information:
Title
Safety/Tolerability
Description
Safety will be evaluated by analyses of incidence of adverse events of interest (possibly related to the class of drug) and other adverse events. Vital signs, ECGs and safety laboratory parameters will also be presented.
Time Frame
Screening to Final Visit (up to approximately 10 weeks for SAD and 14 weeks for MAD)
Secondary Outcome Measure Information:
Title
Pharmacokinetic Profile
Description
To characterize the PK profile of PB1023 after single and multiple ascending doses of PB1023. The following parameters will be evaluated: t1/2, AUC(inf), AUC(0-t), Tmax, Cmax, Elimination Rate Constant, Clearance and Distribution.
Time Frame
SAD: Pre-dose, 1, 4, 8, and 12 hours post-dose and Day 1, 2, 3, 5, 7, 10, 14, 21 and 28. MAD: Pre-dose, 1, 4, 8, and 12 hours post-dose and Day 1, 2, 3, 5, pre-dose Days 7, 14 and 21 and at 1, 4, 8, and 12 hours post-dose and Day 22, 23, 26, 28, 35, 42,
Title
Pharmacodynamic Response
Description
To assess the pharmacodynamic response of various single and multiple doses of PB1023 (daily fasting plasma glucose and serial glucose (and continuous monitoring as defined in time frame), c-peptide and insulin levels in response to a liquid mixed meal tolerance test (MMTT) pre and post dose) on subjects washed off their baseline oral antihyperglycemic agents.
Time Frame
Fasting plasma glucose collected the day before dosing and with PK samples, excluding day of dosing. SAD MMTT to occur on day 0 and 2, MAD MMTT to occur on Day 0 and 22 with continuous glucose monitoring on Day -8/-7 to Day 0 and on Day 21 to Day 28.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males or post menopausal or surgically sterile females age 18-75 years of age inclusive.
Diagnosed with T2DM for > or = 6 months with HbA1c > or = 6.0% but < or = 9.0% while taking stable doses of one oral antihyperglycemic agent but < or = 8.5% when taking two oral antihyperglycemic agents for up to a maximum of 3 months prior to screening.
Fasting Plasma glucose between 115 mg/dL and 269 mg/dL.
Fasting C-peptide of > or = 0.8 ng/mL.
BMI < or = 40 kg/m2.
Otherwise stable health except for T2DM.
Exclusion Criteria:
Currently taking a non-oral antihyperglycemic agent.
Have taken a PPARg agonist within 90 days of screening.
Known allergy to an approved or investigational GLP-1 receptor analog/agonist.
Unstable cardiovascular disease as defined in clinical protocol.
History, symptoms or signs of pancreatitis or severe gastrointestinal disease.
Personal or family history of medullary thyroid tumors history of Multiple Endocrine Neoplasia Syndrome Type 2.
Poor glucose control as defined in clinical protocol.
Clinically significant renal and/or hepatic dysfunction as defined in clinical protocol.
Absolute requirement for corticosteroids or received systemic steroids within 90 days prior to PB1023 administration.
Pregnant or lactating females.
Known history or active alcohol or drug abuse within 12 months prior to screening.
Positive for HIV, Hepatitis B surface antigen or Hepatitis C antibodies.
Participating in any other study within 30 days prior to screening.
Other medical or psychiatric condition which in the opinion of the investigator would place the subject at increased risk.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark Matson, M.D.
Organizational Affiliation
Prism Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
Diablo Clinical Research
City
Walnut Creek
State/Province
California
ZIP/Postal Code
94598
Country
United States
Facility Name
Prism Research
City
Saint Paul
State/Province
Minnesota
ZIP/Postal Code
55114
Country
United States
Facility Name
Rainier Clinical Research Center, Inc.
City
Renton
State/Province
Washington
ZIP/Postal Code
98057
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs